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Of the more than 1 million Americans who suffer recog-
nized myocardial infarctions (MIs) annually, about 300,000
die in the first year, and a similar number fall victim to
crippling heart failure (HF) (1). Although advances in
revascularization and HF therapies have somewhat blunted
its devastating impact, this modern-day scourge remains an
important clinical challenge. Heart failure following MI can
result from the acute loss of myocytes in the infarct zone,
but more often is precipitated by the delayed and progressive
pathologic remodeling of the ventricle. In this issue of the
Journal, Abbate et al. (2) examine the relationship between
apoptotic death of cardiac myocytes in the infarcted and
noninfarcted regions, and the subsequent development of
HF in patients with recent MI.
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Current understanding of the pathophysiology of MI has
been modified to incorporate observations that myocytes die
by apoptosis, as well as necrosis (3,4). Apoptosis is a suicide
process that is hardwired into all metazoan cells. The death
machinery can be activated by signals originating outside
(for example, deficiencies of nutrients/oxygen/survival fac-
tors, reactive oxygen species, stretch, ultraviolet radiation,
drugs) or inside (such as cell cycle perturbations, deoxyri-
bonucleic acid damage) the cell. The executioners of apo-
ptosis are a family of cysteine proteases called caspases that
cleave proteins following aspartic acid residues (5). Synthe-
sized as largely inert proenzymes, caspases themselves are
activated by proteolytic cleavage and reassembly of subunits
into an active holoenzyme. Caspases then cut multiple
cellular proteins to bring about the orderly demise of the
cell. Caspase activation is regulated by two central death
pathways. One involves the activation of cell surface death
receptors by death ligands (6); in the other, the mitochon-
drial release of apoptotic activators, such as cytochrome c, is
the critical event (7). Both of these central death pathways,
and interconnections between them, have been shown to
mediate apoptosis in cardiac myocytes (8–10).
Work in rodent models of myocardial infarction indicates
that most cell death in the first 2 to 4 h following coronary
occlusion occurs by apoptosis (3,8,11,12). Necrosis becomes
more prominent between 6 and 24 h (3). Cell death in the
infarct zone is large in magnitude (5,000/105 to 30,000/105
or 5% to 30% of the myocytes in the heart) but short in
duration (mostly complete in 24 h) (Table 1) (8,12–14).
Left ventricular remodeling begins within hours to days and
continues for months (15,16). Initially, remodeling may
involve side-to-side slippage of myocytes, resulting in in-
farct expansion. Later, in response to volume overload and
neurohumoral signals, the noninfarcted remote myocardium
undergoes hypertrophy, which initially helps to decrease
wall stress. Ultimately, however, the left ventricle dilates, its
walls thin, and contractile function deteriorates.
Although the precise cellular and molecular bases of these
complex remodeling events are not known, myocyte apo-
ptosis in the noninfarcted remote myocardium appears to be
involved. In contrast to the high-frequency, short-lived
burst of cell death that occurs during the first 24 h in the
infarct zone, myocyte apoptosis in the remote myocardium
is infrequent (10/105 to 100/105 in rodent studies
[11,14,17]; 200/105 to 750/105 in human studies [13,18–
20]) and can persist for months. For reference, hearts from
normal rodents and humans exhibit a baseline frequency of
apoptosis of 1/105 to 10/105 (8,11–13,18,20,21). Does the
low, but abnormal, rate of myocyte apoptosis in the remote
myocardium contribute substantially to myocyte loss? To
answer this question, one needs to know the time required
for a myocyte to undergo apoptosis during myocardial
infarction in vivo. This is not known, and on the basis of
studies with cultured cells including adult cardiac myocytes,
could range from 1 to 24 h (22–24). If we arbitrarily take
12 h as the time required for myocyte apoptosis to occur in
vivo and 500/105 as the apoptotic frequency in the remote
myocardium, then approximately 1% of the myocytes in the
remote myocardium would be lost per day. Although some
of this cell loss may be mitigated by replacements derived
from stem cell populations, the impact of this myocyte
death could be considerable and is consistent with the 10- to
62-day time course of demise of the patients studied by
Abbate et al. (2). We emphasize that these kinds of
calculations are at best gross approximations because of
assumptions concerning the time required for myocyte
apoptosis to take place in vivo.
It is interesting to note that the frequency of myocyte
apoptosis in the remote myocardium following human
myocardial infarction (200/105 to 750/105) is very similar to
that observed in three independent human studies of end-
stage dilated cardiomyopathy (80/105 to 250/105)
(18,20,21). This is in keeping with the notion that, regard-
less of inciting etiology, low but abnormal rates of myocyte
apoptosis play a role in the transition to heart failure. The
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Table 1. Previous Work Demonstrating Apoptosis in Myocardial Infarction and Heart Failure
Study Name Model Species Status of IRA
Apoptotic Rate (/105 cells)
Infarct Zone Border Zone
Remote
Myocardium
Control
Level
Olivetti et al. (13) Post-MI (4 days) Human [postmortem] 5/15 Occluded n/a 11,590 740 0
Saraste et al. (19) Post-MI (1–2 days) Human [postmortem] Patent 39 806 5 7
Olivetti et al. (18) CHF [80–190 mon] (Ischemic
n  20, Idiopathic n  18,
Valvular n  1)
Human [explant/postmortem] n/a n/a n/a 232 (overall) 1
243 (ischemic)
236 (idiopathic)
102 (valvular)
Saraste et al. (19) CHF (progression to allograft) Human [explant] n/a n/a n/a 119 (overall) 11
192 (rapid)
93 (intermediate)
26 (slow)
Guerra et al. (20) CHF Human [explant] n/a n/a n/a 80 (female) 2
180 (male)
Abbate et al. (33) Post-MI (12–62 days) Human [postmortem] 8/24 Patent 25,800 (occ. IRA) n/a 500 (overall) n/a
2,300 (pat. IRA) 300 (patent IRA)
25,400 (overall)
Baldi et al. (34) Post-MI (12–62 days) Human [postmortem] 2/16 Patent 26,000 (occ. IRA) n/a 700 (overall) n/a
4,500 (pat. IRA)
Cheng et al. (11) Post-MI (20 min–1 mon) Rat [in vivo] Occluded n/a 70 8 0
Fliss et al. (12) Post MI/I-R (4 h) Rat [in vivo] Occluded/Open 23,000 (I-R) n/a n/a 0
33,000 (MI)
Bialik et al. (8) Post-MI (4–48 h) Mouse [in vivo] Occluded 3,000–12,000 0
Sam et al. (17) Post MI (1 day–12 weeks) Mouse [in vivo] Occluded n/a n/a 75–100 25
Palojoki et al. (14) Post-MI Rat [in vivo] Occluded 1,000 (1 day)
subsequently
undetectable
4,900 (1 day) 70–90 30
100–200 (1–12 weeks)
Wencker et al. (25) CHF Mouse [in vivo] n/a n/a n/a 23 1.5
CHF  congestive heart failure; I-R  ischemia-reperfusion; IRA  infarct related artery; MI  myocardial infarction; n/a  not applicable.
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sufficiency of these low rates of myocyte apoptosis to induce
HF has been demonstrated in a transgenic mouse model of
low-level caspase-8 activation in which apoptotic rates of
only 23/105 are adequate to induce a lethal dilated cardio-
myopathy over several months (25). If this rate of apoptosis
is sufficient to create a dilated cardiomyopathy de novo, it is
reasonable to posit that even less myocyte loss in the remote
myocardium may be required to precipitate failure in hearts
that have previously suffered a large infarction.
Studies in which myocyte apoptosis has been inhibited by
various genetic and pharmacologic means have demon-
strated decreases in infarct size, left ventricular dilation,
contractile dysfunction, and, in some cases, mortality in
various rodent models of ischemia-reperfusion (10,26–30)
and HF (25,31,32). These results establish that apoptosis
plays an important role in the pathogenesis of heart disease
in these rodent models and suggest that inhibition of
myocyte death may provide a target for new therapies.
Further work will be needed to test the extent to which
these results can be extrapolated to the human syndromes.
In this issue of the Journal, Abbate et al. (2) address the
important question of the role of myocyte apoptosis in the
genesis of left ventricular dilation and thinning of nonin-
farcted remote myocardium following human MI. Their
approach was to identify clinical and pathophysiologic
correlates of accelerated myocyte apoptosis (2) in a post-
mortem study. The population consists of 14 patients dying
from atraumatic causes 10 to 62 days following MI with a
persistently occluded infarct-related artery. Most were men
in their seventies, had large (30%) transmural infarcts,
clinical evidence of congestive heart failure, and a short
median survival of 16 days following the infarction. Of the
14 patients, 8 had multivessel coronary disease and 7 had
suffered a prior infarction 6 months earlier. Only one
patient was diabetic. As per the authors, none of the
patients had clinical or pathologic evidence of reinfarction.
The major conclusions were: 1) the apoptotic rate in the
remote myocardium correlated strongly with thinning of
this region; 2) the apoptotic rate in the infarct area corre-
lated strongly with left ventricular dilation; and 3) apoptotic
rates in the infarct zone and remote myocardium both
correlated with symptomatic evidence of heart failure.
These findings are novel in that they directly correlate
specific features of postinfarct remodeling with apoptotic
rates.
One aspect of the data that is at variance with previous
work is the apoptotic rate reported for the infarct zone 10 to
62 days following the acute event (approximate mean of
18% or 18,000/105). The authors suggest that this high rate
may reflect selection bias for exceptionally sick patients. It
seems unlikely, however, that these rates of apoptosis could
be sustained for so prolonged a period. Whether they reflect
an ischemic event immediately before death or perhaps
medications such as inotropes is unclear. Alternatively, the
massive loss of total nuclei in the infarct zone from the
initial infarction may have artifactually elevated the percent-
ages by decreasing the denominator (8).
This study provides new information beyond that avail-
able in previous human studies (13,19,33,34). The direct
correlation of apoptotic rates in the infarct and remote
myocardium with left ventricular chamber size and wall
thickness, respectively, suggest that myocyte apoptosis plays
an important role in both aspects of remodeling. This
information may help provide a baseline for future studies of
anti-apoptosis therapies in humans.
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